Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,733 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Coincidental items in the definition of metabolic dysfunction-associated fatty liver are useful in identifying patients having significant fibrosis with fatty liver.
Kakisaka K, Kuroda H, Abe T, Nakaya I, Watanabe T, Yusa K, Sato H, Suzuki A, Kooka Y, Endo K, Yoshida Y, Oikawa T, Miyasaka A, Matsumoto T. Kakisaka K, et al. Among authors: suzuki a. Hepatol Res. 2023 Sep;53(9):857-865. doi: 10.1111/hepr.13928. Epub 2023 Jun 15. Hepatol Res. 2023. PMID: 37269213
Positive impact of obesity on the prognosis of liver cirrhosis.
Endo K, Kakisaka K, Abe T, Yusa K, Nakaya I, Watanabe T, Suzuki A, Yoshida Y, Oikawa T, Miyasaka A, Kuroda H, Matsumoto T. Endo K, et al. Among authors: suzuki a. J Gastroenterol Hepatol. 2024 Aug;39(8):1663-1672. doi: 10.1111/jgh.16590. Epub 2024 May 3. J Gastroenterol Hepatol. 2024. PMID: 38700075
Grip strength complements performance status in assessing general condition in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
Endo K, Kakisaka K, Abe T, Yusa K, Nakaya I, Watanabe T, Abe H, Suzuki A, Yoshida Y, Oikawa T, Miyasaka A, Kuroda H, Matsumoto T. Endo K, et al. Among authors: suzuki a. Hepatol Res. 2024 Dec;54(12):1158-1173. doi: 10.1111/hepr.14084. Epub 2024 Jun 15. Hepatol Res. 2024. PMID: 38877962
Early Clinical Outcomes of Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma: A Real-World Comparison with First-Line or Later-Line Treatment.
Fujiwara Y, Kuroda H, Abe T, Kakisaka K, Nakaya I, Ito A, Watanabe T, Yusa K, Nagasawa T, Sato H, Suzuki A, Endo K, Yoshida Y, Oikawa T, Sawara K, Miyasaka A, Matsumoto T. Fujiwara Y, et al. Among authors: suzuki a. Drugs Real World Outcomes. 2024 Dec;11(4):701-710. doi: 10.1007/s40801-024-00458-7. Epub 2024 Oct 10. Drugs Real World Outcomes. 2024. PMID: 39384684 Free PMC article.
6,733 results